About the study The current study performed a randomized, double-blind, crossover trial at the Research Institute of the McGill University Health Centre in Montreal, Quebec, Canada, to investigate whether semaglutide improved glycemic control and other nonglycemic outcomes in patients with T1D and using AID
Recommended reconstitution volumes: 5mg vial add 2.5mL BAC water (2mg/mL)
Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which mimics both GLP-1 and GIP, are synthetic versions of these hormones
SGLT2is cause weight loss by decreasing body water due to osmotic diuresis and by increasing the excretion of calories in the urine [11]
Semaglutide produced 14.9% mean weight loss in STEP-1 at 68 weeks